AstraZeneca's TRUQAP showed significant progress in treating aggressive prostate cancer, with better survival rates.

AstraZeneca's new treatment, TRUQAP, combined with abiraterone and androgen deprivation therapy, significantly improved progression-free survival in patients with a specific type of aggressive prostate cancer compared to standard treatment. The treatment showed promising early results in overall survival and had a consistent safety profile. The data will be presented at an upcoming medical meeting and shared with regulators.

November 25, 2024
3 Articles

Further Reading